Citadel Advisors
ZYME icon

Citadel Advisors’s Zymeworks ZYME Stock Holding History

Citadel Advisors’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,400
Closed -$336K – 15032
2026
Q1 		$336K Sell
13,400
-17,200
-56% -$407K ﹤0.01% 10220
2025
Q4 		$806K Buy
+30,600
New +$667K ﹤0.01% 7903
2025
Q3 		– Sell
-12,900
Closed -$162K – 14334
2025
Q2 		$162K Sell
12,900
-700
-5% -$8.34K ﹤0.01% 10887
2025
Q1 		$162K Buy
13,600
+7,100
+109% +$96.8K ﹤0.01% 10748
2024
Q4 		$95.2K Sell
6,500
-3,800
-37% -$53.1K ﹤0.01% 11555
2024
Q3 		$129K Buy
10,300
+1,900
+23% +$20.7K ﹤0.01% 10770
2024
Q2 		$71.5K Sell
8,400
-2,700
-24% -$24K ﹤0.01% 11354
2024
Q1 		$117K Buy
11,100
+4,300
+63% +$47.7K ﹤0.01% 11141
2023
Q4 		$70.7K Sell
6,800
-2,200
-24% -$17.5K ﹤0.01% 11379
2023
Q3 		$57.1K Sell
9,000
-18,300
-67% -$135K ﹤0.01% 11594
2023
Q2 		$236K Buy
27,300
+11,500
+73% +$103K ﹤0.01% 9526
2023
Q1 		$143K Sell
15,800
-17,500
-53% -$153K ﹤0.01% 10722
2022
Q4 		$262K Buy
+33,300
New +$234K ﹤0.01% 9610
2022
Q2 		– Sell
-26,000
Closed -$170K – 14276
2022
Q1 		$170K Buy
26,000
+5,300
+26% +$47.2K ﹤0.01% 11708
2021
Q4 		$339K Sell
20,700
-1,900
-8% -$39.6K ﹤0.01% 10657
2021
Q3 		$656K Sell
22,600
-7,100
-24% -$236K ﹤0.01% 9228
2021
Q2 		$1.03M Sell
29,700
-4,000
-12% -$127K ﹤0.01% 8294
2021
Q1 		$1.06M Buy
33,700
+16,200
+93% +$658K ﹤0.01% 7960
2020
Q4 		$827K Buy
17,500
+11,500
+192% +$534K ﹤0.01% 7189
2020
Q3 		$279K Sell
6,000
-12,400
-67% -$426K ﹤0.01% 8251
2020
Q2 		$664K Sell
18,400
-6,000
-25% -$221K ﹤0.01% 6568
2020
Q1 		$865K Buy
24,400
+13,700
+128% +$561K ﹤0.01% 5588
2019
Q4 		$486K Buy
+10,700
New +$389K ﹤0.01% 6845

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Citadel Advisors's ZYME Position: Q2 2026 in Review

Citadel Advisors reduced its Zymeworks (ZYME) stake by 21% in Q2 2026, selling an estimated $5.99M and leaving 914,136 shares worth $23.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2341.

Citadel Advisors first reported a position in ZYME in Q4 2017 and has held it in 31 quarters since. The position peaked at $33.1M in Q2 2020. 203 funds tracked by Wall St. Rank hold ZYME as of Q2 2026.

  • Citadel Advisors held 914,136 shares of Zymeworks worth $23.9M as of Q2 2026.
  • Citadel Advisors sold 235,882 Zymeworks shares in Q2 2026, an estimated $5.99M.
  • Zymeworks made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2341 holding.
  • Citadel Advisors first reported a position in Zymeworks in Q4 2017 and has held it in 31 quarters since.
  • Citadel Advisors's Zymeworks position peaked at $33.1M in Q2 2020.
  • 203 funds tracked by Wall St. Rank held Zymeworks as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.